U.S. markets closed

Sigilon Therapeutics, Inc. (SGTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.0000-0.1200 (-2.34%)
At close: 4:00PM EDT
5.0000 0.00 (0.00%)
After hours: 04:00PM EDT
Sign in to post a message.
  • S
    Pick up shares now and up. Lots of institutional investors picking up shares over the last few trading days, increasing the daily volume. Lots of buying around 15 to 20$. Once the trial hold is lifted something is going to happen.
  • L
    My fellow longs, what's verdict? Jump ship or hold on tight? I've never been down 50% before
  • d
    will this stock go up to $40 or so in the near future as got 325 shares now at $6.77 avg

    if so i will keep it at least 6 months then will make alot of money.

    any ideas?
  • R
    This is going to pay big soon so buckle up and enjoy the ride back up!!
  • a
    does anybody knows why is this halted? is there good news coming?
  • B
    How many in the trial? The share price is getting so low that LLY might be better buying the company with the milestone payments it is committed to make.
  • T
    The Hobbyist
    What I found interesting in SGTX clinical hold's press release is that the complications were well known.

    "To date, three patients have been dosed with SIG-001. The third patient, who received the highest dose of study drug, developed inhibitors to Factor VIII (FVIII) — a well-known complication of FVIII therapy"

    Hence, I think SIG-001 is still valuable, just a matter of controlling the dose! only coming days will tell.

    Company value is close to the cash they hold; the market is overreacting indeed.
  • C
    I'm ready for some good news
  • S
    The third patient, who received the highest dose of the study drug, developed inhibitors to Factor VIII (FVIII), a known complication of FVIII therapy. However, the patient is responding well to medical treatment.

    "The intensity of the first FVIII exposure is postulated to be a risk factor for inhibitor formation because significant cell injury or inflammation leads to immunologic ‘danger signals’ that stimulate antigen-presenting cells and amplify an immunologic response which could promote inhibitor development [Gallucci and Matzinger, 2001; Kono and Rock, 2008; Matzinger, 2002]. Several studies have demonstrated an increased rate of inhibitor formation after intensive treatment (i.e. surgical procedure or high-frequency treatment) [Gouw et al. 2007a, 2007b; Maclean et al. 2011; Ragni et al. 2009a]. However, a case–control study by Santagostino and colleagues did not confirm these findings [Santagostino et al. 2005]. Overall it does appear that there is an increased risk of inhibitor formation after an intense initial FVIII exposure. This association is not a reason to withhold life-saving therapy but should prompt a clinician at the time of a significant early exposure to monitor closely for the development of an inhibitor."

    They just need to decrease the dose - numbers of spheres that contain cells releasing Factor VIII. But overall it's good data for SGTX - their technology works very effectively. This company is a leader in cell-based therapy. Current MC is equal to cash they have on the hands - it's just ridiculous. Cell-based therapy definitely can compete with gene therapy and it's cheaper and more safe. SGTX small spheres (cages containing genome modified cells) work like small syringes continuously injecting patients with needed substances. SGTX has a big portfolio for numerous diseases. Pps should be at least $20
  • n
    SP so low? Where is the bottom?
  • K
    It was my understanding that SGTX's technology was supposed to prevent the body from developing inhibitors (abs) to FVIII. High dose triggered another pathway? Other preconditions? Will be interesting to follow investigation.
  • n
    Once the suspension is lifted, this will blow up back to my average 21
  • n
    Why is it up 10% premarket?
  • D
    New investor here. This seems pretty promising. Currently trading at cash value and have a deal worth half billion with Eli Lilly for diabetes. Easily can return to $40+. Latest pause on their trial by the FDA sounds like it wasn't a result of their technology failing but a result of too high of a dose because its a known issue with this type of therapy.
  • s
    Just started a position low 9’s
  • P
    Little Volume but it’s picking up. Might be a good time to buy
  • M
    How confident you are in this stock? Please share your thoughts.
  • 5
    is it good time to buy now ? at $10 ?
  • Y
    Yahoo Finance Insights
    Sigilon Therapeutics is down 25.32% to 6.90
  • K
    Someone likes this company...just bought 75,000 shares